Table 4.
Characteristics | Quetiapine group (n=89) | Placebo group (n=89) | All patients (n=178) |
---|---|---|---|
Mean (SD) age (years) | 23.5 (5.2) | 24.9 (7.3) | 24.2 (6.4) |
Mean (SD) age at onset (years) | 21.4 (5.3) | 22.4 (7.5) | 21.9 (6.5) |
Male sex | 39 (44) | 41 (46) | 80 (45) |
Mean (SD) education (years) | 12.0 (2.6) | 11.7 (3.1) | 11.8 (2.8) |
Employed | 62 (70) | 65 (73) | 127 (71) |
Type of disorder: | |||
Schizophrenia | 46 (52) | 45 (51) | 91 (51) |
Schizophreniform disorder | 15 (17) | 12 (13) | 27 (15) |
Schizoaffective disorder | 3 (3) | 6 (7) | 9 (5) |
Brief psychotic disorder | 13 (15) | 8 (9) | 21 (12) |
Psychosis not otherwise specified | 12 (13) | 18 (20) | 30 (17) |
Comorbid diagnoses: | |||
Affective disorder | 5 (6) | 2 (2) | 7 (4) |
Previous substance abuse | 2 (2) | 4 (4) | 6 (3) |
Personality disorder | 0 | 1 (1) | 1 (1) |
Others | 1 (1) | 0 | 1 (1) |
Mean (SD) PANSS21 sum score (n=177): | |||
Total | 36.1 (4.6) | 37.1 (6.4) | 36.6 (5.6) |
Positive | 7.2 (0.6) | 7.3 (0.7) | 7.2 (0.6) |
Negative | 8.7 (2.9) | 9.1 (3.6) | 8.9 (3.3) |
Mean (SD) CGI27 severity score (n=176) | 1.1 (0.3) | 1.2 (0.4) | 1.1 (0.3) |
Mean (SD) SOFAS30 score* | 76.4 (10.0) | 74.6 (11.7) | 75.5 (10.9) |
Mean (SD) PAS31† (n=157) | 2.7 (0.9) | 2.8 (0.8) | 2.8 (0.9) |
Mean (SD) PSST32‡ (n=160) | 1.5 (0.5) | 1.5 (0.4) | 1.5 (0.5) |
CGI=clinical global impressions; PANSS=positive and negative syndrome scale; PAS=premorbid adjustment scale; PSST=assessment of premorbid schizoid and schizotypal traits; SOFAS=social and occupational functioning assessment scale.
*Range of scores from 1 to 100, with lower scores representing impaired functioning.
†Measures functional level before onset of illness, with range of scores from 10 to 70 and lower scores indicating better functioning.
‡Measures premorbid personality in patients before first episode psychosis on basis of interview of an informant, with range of scores from 8 to 32 and lower scores indicating fewer schizoid-schizotypal traits.